With Luncolive, Orixha aims to promote the Liquid Ventilation as a new breakthrough technology in critical care. Link to the press release (in french)
Orixha announce that its Luncolive program has been selected by the European Innovation Council for a founding of 2.5 M€ and a capital investment of 5 M€, in order to
improve the survival of post-cardiac arrest patients. This will allow to validate the clinical benefit of the Vent2Cool Solution in post-cardiac arrest syndrome and to
explore and developp new medical applications in critical care
On march 31st, Orixha won the first prize of Innovation at Medi'Nov salon 2022. This competition was organized by the region Auvergne-Rhône-Alpes in France.
Link to the press release (in french)
Orixha just annonced a foundraising of 2 millions euros from Angels Santé, Erganeo and its industrial partners : Infiplast, OEM Development et Activation. This first round will allow to finalize the medical device Vent2Cool before starting the first clinical trial in cardiac arrest patients.
Link to the press release (in french)
Orixha
7 avenue du Général de Gaulle
94700, Maisons-Alfort
France
Suivez nous sur Twitter 
et
sur Linkedin 
The data on this website is provided exclusively for information purposes. Orixha does not guarantee completeness or accuracy of the information displayed. Information displayed on this website does not constitute a solicitation or an investment offer or advice nor does it create any legal relationship of whatsoever nature
